Product Details
| Product Name:
palovarotene |
CAS No.:
410528-02-8 |
| Purity:
98.05% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | palovarotene |
| Description | Palovarotene (Ro 3300074) is an agonist of nuclear retinoic acid receptor γ (RAR-γ). |
| In vivo | Palovarotene effectively hinders post-traumatic chondrogenesis, osteogenesis, and significantly reduces trauma-induced ectopic bone formation. Through oral administration (1 mg/kg/day for 14 days, starting from either the first or fifth day post-operation), this compound markedly decreases subcutaneous and intramuscular heterotopic ossification (HO) in mice, achieving a reduction of 50 to 60% in HO, irrespective of treatment initiation timing or infection presence. In a specific study, Acvr1cR206H/+ mice were divided into two groups: one treated with Palovarotene and the other with a vehicle control for 14 days beginning on the injury's first day. Comparative analysis using micro-CT and 3D imaging on the 14th day revealed that while significant HO tissue masses developed in the vehicle-treated group, Palovarotene-treated mice showed over an 80% reduction in HO formation, based on bone volume/total volume metrics. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 5.5 mg/mL (13.27 mM)
|
| Keywords | RAR/RXR | inhibit | Retinoid X receptors | R667 | Autophagy | palovarotene | Ro-3300074 | Retinoic acid receptors | Inhibitor | R-667 | Ro3300074 |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:42017-89-0
$30.00 / 1mL
-
CAS:1345982-69-5
$76.00 / 1mg
-
CAS:1351758-81-0
$53.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00/1g |
VIP5Y
|
Career Henan Chemical Co
|
2020-01-10 |
United States